In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Beyondspring Inc (NASDAQ: BYSI), with a price target of $48. The company’s shares opened today at $21.50, close to its 52-week low of $19.15.
McCarthy wrote:
“BeyondSpring announced phase 2 data demonstrating prevention of Thrombocytopenia in patients receiving Plinabulin. The poster titled “Plinabulin, a in NSCLC Patients” will be presented on 9/24 at the Cancer (IASLC).”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 17.7% and a 51.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Beyondspring Inc is a Moderate Buy with an average price target of $54.
See today’s analyst top recommended stocks >>
Based on Beyondspring Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.66 million. In comparison, last year the company had a GAAP net loss of $13.34 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
